Table 3.
Adverse events during treatment presented
| Participants who experience an adverse event | Adverse events per dose of OIT | |
|---|---|---|
| Symptoms | ||
| Mouth itch | 76 (81%) | 1121 (6·30%) |
| Abdominal pain | 54 (57%) | 460 (2·59%) |
| Nausea | 31 (33%) | 393 (2·21%) |
| Vomiting | 31 (33%) | 134 (0·75%) |
| Diarrhoea | 1 (1%) | 5 (0·03%) |
| Urticaria | 12 (13%) | 29 (0·16%) |
| Angio-oedema | 18 (19%) | 71 (0·40%) |
| Erythema | 20 (21%) | 41 (0·23%) |
| Rhinitis | 23 (24%) | 65 (0·37%) |
| Wheezing | 21 (22%) | 73 (0·41%) |
| Laryngeal oedema | 1 (1%) | 1 (0·01%) |
| Cardiovascular collapse or fainting | 0 | 0 |
| Outcome | ||
| Admission to intensive-care unit, serious adverse reaction, or serious unexpected suspected adverse reaction | 0 | 0 |
| Use of inhaled β2 agonist | 18 (19%) | 63 (0·35%) |
| Use of intramuscular adrenaline | 1 (1%) | 2 (0·01%) |
Data are n (%). Total doses were 17 793. OIT=oral immunotherapy.